Lv1
38 积分 2024-10-29 加入
[Multiple myeloma and other plasma cell dyscrasias]
10小时前
待确认
Blurring the Lines: Beyond Using Transplant Eligibility to Guide Induction Therapy in Myeloma
2个月前
已关闭
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
2个月前
已完结
Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study
2个月前
已关闭
Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA
2个月前
已完结
Challenges for Chinese innovative cancer drugs in going global: insights from multiregional clinical trials
3个月前
已完结
MM-711: Safety Outcomes Following Frontline Daratumumab-Based Therapy in Multiple Myeloma: A Systematic Reviewand Meta-Analysis
3个月前
已关闭
Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA
3个月前
已完结
Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma
3个月前
已完结
Preclinical Development and Validation of ASP5354: A Near-Infrared Fluorescent Agent for Intraoperative Ureter Visualization
5个月前
已完结
皖公网安备34019202002308
